Reports
Sale
North America Viral Vector Manufacturing Market Size, Share: By Type: Adenoviral Vectors, Adeno-associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Others; By Disease: Cancer, Genetic Disorders, Infectious Diseases, Others; By Expression System; By Application; By End User; Regional Analysis; Supplier Landscape; 2024-2032
North America Viral Vector Manufacturing Market Outlook
The North America viral vector manufacturing market size was valued at USD 4.2 billion in 2023, driven by the increased funding for the development of gene therapies in the region. The market is expected to grow at a CAGR of 7.16% during the forecast period of 2024-2032, with the values likely to rise from USD 4.5 billion in 2024 to USD 7.9 billion by 2032.
Key Takeaways
- In November 2023 , Genezen secured USD 18.5 million funding to strengthen its growth trajectory in viral vector manufacturing as well as enable better support to its growing clientele of cell and gene therapy innovators.
- The North America viral vector manufacturing market share is significantly impacted by the rising preference for personalised medicines to tackle chronic diseases.
- In September 2023 , Thermo Fisher Scientific expanded the scale of its production at its viral vector manufacturing site worth USD 180 million. Located at Plainville, Massachusetts, the development is projected to boost viral vector production as well as gene therapy production.
In North America, the market is witnessing steady growth driven by the rising demand for gene therapy, vaccines, and other innovative therapeutics to tackle the growing burden of genetic disorders, chronic diseases, and infectious diseases, among others. Viral vectors such as adeno-associated viruses, adenoviruses, and lentiviruses are increasingly employed for gene transfer in gene therapy. The substantial funding for the development of gene therapies is expected to drive the North America viral vector manufacturing market growth in the forecast period. In November 2023 , a study published in Nature estimated the annual spending on gene therapy to be USD 20.4 billion in the United States. This rising investment in the biotechnology sector is likely to boost the market size.
One of the significant market trends is the expansion of viral vector development and manufacturing capabilities by the key market players supported by major financial investments. In November 2023 , Genezen, a contract development and manufacturing organization (CDMO) in the United States, secured USD 18.5 million in financing led by Ampersand Capital Partners which aimed to strengthen its growth trajectory in viral vector manufacturing as well as enable better support to their cell and gene therapy innovators. Such investments are also poised to foster technological innovation and expansion of manufacturing sites and is expected to meet the growing North America viral vector manufacturing market demand.
In September 2023 , Thermo Fisher Scientific expanded the scale of its production at its viral vector manufacturing site worth USD 180 million. Situated at Plainville, Massachusetts, the company intended to make use of its 400,000 square feet viral vector manufacturing unit to boost viral vector production along with gene therapy production simultaneously. These initiatives mark as one of the most impactful North America viral vector manufacturing market trends, expected to help in accelerating the development and commercialization of life-saving therapies which will ultimately impact the market dynamics.
Other factors that influence the market share include the advancement in the healthcare infrastructure, increased research efforts aimed at finding novel therapeutics, and the improvement in regulatory reforms.
North America Viral Vector Manufacturing Market Segmentation
North America viral vector manufacturing market analysis include a detailed breakup of the market based on the following segments:
| Market Breakup | Categories |
| Type | Adenoviral Vectors, Adeno-associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Others |
| Disease | Cancer, Genetic Disorders, Infectious Diseases, Others |
| Expression System | Transient, Stable |
| Application | Gene Therapy, Vaccinology, Therapeutics Development, Research |
| End User | Pharmaceutical and Biotechnology Companies, Research Institutes, CDMO & CROs, Others |
| Countries | United States of America, Canada |
North America Viral Vector Manufacturing Market: Competitor Landscape
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Charles River Laboratories
- Finvector
- Kaneka Eurogentec SA
- Merck KGaA
- UniQure NV
- Oxford Biomedica PLC
- AstraZeneca
- Vibalogics
- Sanofi
- F.Hoffmann-La Roche Ltd
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Disease |
|
| Breakup by Expression System |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 North America Viral Vector Manufacturing Market Overview
3.1 North America Viral Vector Manufacturing Market Historical Value (2017-2023)
3.2 North America Viral Vector Manufacturing Market Forecast Value (2024-2032)
4 North America Viral Vector Manufacturing Market Landscape*
4.1 North America Viral Vector Manufacturing: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 North America Viral Vector Manufacturing: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Disease
4.2.3 Analysis by Application
5 North America Viral Vector Manufacturing Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 North America Viral Vector Manufacturing Market Segmentation (2017-2032)
6.1 North America Viral Vector Manufacturing Market (2017-2032) by Type
6.1.1 Market Overview
6.1.2 Adenoviral Vectors
6.1.3 Adeno-associated Viral Vectors
6.1.4 Lentiviral Vectors
6.1.5 Retroviral Vectors
6.1.6 Others
6.2 North America Viral Vector Manufacturing Market (2017-2032) by Disease
6.2.1 Market Overview
6.2.2 Cancer
6.2.3 Genetic Disorders
6.2.4 Infectious Diseases
6.2.5 Others
6.3 North America Viral Vector Manufacturing Market (2017-2032) by Expression System
6.3.1 Market Overview
6.3.2 Transient
6.3.3 Stable
6.4 North America Viral Vector Manufacturing Market (2017-2032) by Application
6.4.1 Market Overview
6.4.2 Gene Therapy
6.4.3 Vaccinology
6.4.4 Therapeutics Development
6.4.5 Research
6.5 North America Viral Vector Manufacturing Market (2017-2032) by End User
6.5.1 Market Overview
6.5.2 Pharmaceutical and Biotechnology Companies
6.5.3 Research Institutes
6.5.4 CDMO & CROs
6.5.5 Others
6.6 North America Viral Vector Manufacturing Market (2017-2032) by Countries
6.6.1 Market Overview
6.6.2 United States of America
6.6.3 Canada
7 United States of America Viral Vector Manufacturing Market (2017-2032)
7.1 United State of America Viral Vector Manufacturing Market (2017-2032) by Type
7.1.1 Market Overview
7.1.2 Adenoviral Vectors
7.1.3 Adeno-associated Viral Vectors
7.1.4 Lentiviral Vectors
7.1.5 Retroviral Vectors
7.1.6 Others
7.2 United State of America Viral Vector Manufacturing Market (2017-2032) by Disease
7.2.1 Market Overview
7.2.2 Cancer
7.2.3 Genetic Disorders
7.2.4 Infectious Diseases
7.2.5 Others
7.3 United State of America Viral Vector Manufacturing Market (2017-2032) by Expression System
7.3.1 Market Overview
7.3.2 Transient
7.3.3 Stable
7.4 United State of America Viral Vector Manufacturing Market (2017-2032) by Application
7.4.1 Market Overview
7.4.2 Gene Therapy
7.4.3 Vaccinology
7.4.4 Therapeutics Development
7.4.5 Research
7.5 United State of America Viral Vector Manufacturing Market (2017-2032) by End User
7.5.1 Market Overview
7.5.2 Pharmaceutical and Biotechnology Companies
7.5.3 Research Institutes
7.5.4 CDMO &CROs
7.5.5 Others
8 Canada Viral Vector Manufacturing Market (2017-2032)
8.1 Canada Viral Vector Manufacturing Market (2017-2032) by Type
8.1.1 Market Overview
8.1.2 Adenoviral Vectors
8.1.3 Adeno-associated Viral Vectors
8.1.4 Lentiviral Vectors
8.1.5 Retroviral Vectors
8.1.6 Others
8.2 Canada Viral Vector Manufacturing Market (2017-2032) by Disease
8.2.1 Market Overview
8.2.2 Cancer
8.2.3 Genetic Disorders
8.2.4 Infectious Diseases
8.2.5 Others
8.3 Canada Viral Vector Manufacturing Market (2017-2032) by Expression System
8.3.1 Market Overview
8.3.2 Transient
8.3.3 Stable
8.4 Canada Viral Vector Manufacturing Market (2017-2032) by Application
8.4.1 Market Overview
8.4.2 Gene Therapy
8.4.3 Vaccinology
8.4.4 Therapeutics Development
8.4.5 Research
8.5 Canada Viral Vector Manufacturing Market (2017-2032) by End User
8.5.1 Market Overview
8.5.2 Pharmaceutical and Biotechnology Companies
8.5.3 Research Institutes
8.5.4 CDMO &CROs
8.5.5 Others
9 Regulatory Framework
10 Patent Analysis
10.1 Analysis by Type of Patent
10.2 Analysis by Publication year
10.3 Analysis by Issuing Authority
10.4 Analysis by Patent Age
10.5 Analysis by CPC Analysis
10.6 Analysis by Patent Valuation
10.7 Analysis by Key Players
11 Funding and Investment Analysis
11.1 Analysis by Funding Instances
11.2 Analysis by Type of Funding
11.3 Analysis by Funding Amount
11.4 Analysis by Leading Players
11.5 Analysis by Leading Investors
11.6 Analysis by Geography
12 Partnership and Collaborations Analysis
12.1 Analysis by Partnership Instances
12.2 Analysis by Type of Partnership
12.3 Analysis by Leading Players
12.4 Analysis by Geography
13 Supplier Landscape
13.1 Market Share by Top 5 Companies
13.2 Charles River Laboratories
13.2.1 Financial Analysis
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.2.5 Certifications
13.3 Finvector
13.3.1 Financial Analysis
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.3.5 Certifications
13.4 Kaneka Eurogentec SA
13.4.1 Financial Analysis
13.4.2 Product Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.4.5 Certifications
13.5 Merck KGaA
13.5.1 Financial Analysis
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.5.5 Certifications
13.6 UniQure NV
13.6.1 Financial Analysis
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.6.5 Certifications
13.7 Oxford Biomedica PLC
13.7.1 Financial Analysis
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.7.5 Certifications
13.8 AstraZeneca
13.8.1 Financial Analysis
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.8.5 Certifications
13.9 Vibalogics
13.9.1 Financial Analysis
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.9.5 Certifications
13.10 Sanofi
13.10.1 Financial Analysis
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.10.5 Certifications
13.11 F. Hoffmann-La Roche Ltd
13.11.1 Financial Analysis
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.11.5 Certifications
14 North America Viral Vector Manufacturing Market – Distribution Model (Additional Insight)
14.1 Overview
14.2 Potential Distributors
14.3 Key Parameters for Distribution Partner Assessment
15 Key Opinion Leaders (KOL) Insights (Additional Insight)
16 Company Competitiveness Analysis (Additional Insight)
16.1 Very Small Companies
16.2 Small Companies
16.3 Mid-Sized Companies
16.4 Large Companies
16.5 Very Large Companies
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 4.2 billion in 2023 driven by the driven by the increased funding for the development of gene therapies in the region.
The market is anticipated to grow at a CAGR of 7.16% during the forecast period of 2024-2032, likely to reach a market value of USD 7.9 billion by 2032.
The growing prevalence of genetic disorders and the rising healthcare expenditure are fuelling the demand for the market.
One of the significant market trends is the expansion of viral vector development and manufacturing capabilities by the key market players. In November 2023 , Genezen, a contract development and manufacturing organization (CDMO) in the United States, secured USD 18.5 million in financing. The funding was intended at strengthening its viral vector manufacturing capabilities as well as enabling better support to their cell and gene therapy innovators.
Based on the type, the market is segmented into adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, and retroviral vectors, among others.
Expression systems available in the market include transient and stable.
By disease, the market is divided into cancer, genetic disorders, and infectious diseases, among others.
End users of the market are pharmaceutical and biotechnology companies, research institutes, CDMOs & CROs, among others.
Major applications areas of viral vector manufacturing include gene therapy, vaccinology, therapeutics development, and research.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are Charles River Laboratories, Finvector, Kaneka Eurogentec SA, Merck KGaA, UniQure NV, Oxford Biomedica PLC, AstraZeneca, Vibalogics, Sanofi, and F. Hoffmann-La Roche Ltd.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER